Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Bock AM, Feng L, Chauhan A, Falchi L, Merryman R, Godbole S, Thiruvengadam SK, Jallouk AP, Major A, D'Angelo C, Ayers A, Baron K, Farahat OM, Shouse G, Danilov A, Bair S, Lunning M, Bhaskar S, Herrera AF, Sawalha Y, Flowers CR, Crombie JL, Salles G, Epperla N, Ahmed S

Open source

DOI: 10.1182/bloodadvances.2026020171
Published: 2026 Aug 25
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2026020171,
  title = {Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.},
  author = {Bock AM and Feng L and Chauhan A and Falchi L and Merryman R and Godbole S and Thiruvengadam SK and Jallouk AP and Major A and D'Angelo C and Ayers A and Baron K and Farahat OM and Shouse G and Danilov A and Bair S and Lunning M and Bhaskar S and Herrera AF and Sawalha Y and Flowers CR and Crombie JL and Salles G and Epperla N and Ahmed S},
  year = {2026},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2026020171},
  url = {https://doi.org/10.1182/bloodadvances.2026020171}
}

RIS

TY  - JOUR
TI  - Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.
AU  - Bock AM
AU  - Feng L
AU  - Chauhan A
AU  - Falchi L
AU  - Merryman R
AU  - Godbole S
AU  - Thiruvengadam SK
AU  - Jallouk AP
AU  - Major A
AU  - D'Angelo C
AU  - Ayers A
AU  - Baron K
AU  - Farahat OM
AU  - Shouse G
AU  - Danilov A
AU  - Bair S
AU  - Lunning M
AU  - Bhaskar S
AU  - Herrera AF
AU  - Sawalha Y
AU  - Flowers CR
AU  - Crombie JL
AU  - Salles G
AU  - Epperla N
AU  - Ahmed S
PY  - 2026
JO  - Blood advances
DO  - 10.1182/bloodadvances.2026020171
UR  - https://doi.org/10.1182/bloodadvances.2026020171
ER  -

APA

AM, B., L, F., A, C., L, F., R, M., S, G., SK, T., AP, J., A, M., C, D., A, A., K, B., OM, F., G, S., A, D., S, B., M, L., S, B., AF, H., Y, S., CR, F., JL, C., G, S., N, E., & S, A. (2026). Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.. Blood advances. https://doi.org/10.1182/bloodadvances.2026020171

Source records

pubmed · retrieved 2026-09-26T00:56:11.379Z